TABLE 1.
Immunological evaluation of the patient before and after HSC transplantation
| Parameters | Age (6 months) | Age (9 months) | Reference values | At 10th month of HSCT | Reference values |
|---|---|---|---|---|---|
| Leukocyte count (/mm3) | 13,600 | 17,000 | 6800–17,500 | 7700 | 5500–16,500 |
| Absolute lymphocyte count (/mm3) | 4700 | 6100 | 3740–10,500 | 3100 | 2963–11,346 |
| Absolute neutrophil count (/mm3) | 5000 | 7800 | 1100–6800 | 3800 | 1200–9150 |
| Absolute monocyte count (/mm3) | 1700 (↑) | 1500 (↑) | 0–600 | 600 | 0–600 |
| Absolute eosinophil count (/mm3) | 2100 (↑) | 2330 (↑) | 0–300 | 160 | 0–300 |
| IgG (mg/dl) | 759 | 1230 (on IVIG) | 304–1231 | 1182 | 605–1430 |
| IgA (mg/dl) | 91 | 167 | 7–123 | 111 | 30–307 |
| IgM (mg/dl) | 99 | 145 | 32–263 | 67 | 66–228 |
| IgE (IU/ml) | 273 (↑) | - | 1.1–10.2 | 13.3 | 0–60 |
| Specific antibody titers | |||||
| Anti-Hbs IgG (mIU/ml) | 0.06 (↓) | - | 0–10 | - | 0–10 |
| Anti-measles IgG (IU/L) | 2.23 | - | >1.1 | - | >1.1 |
| Anti-mumps IgG (AI) | 1.0 (↓) | - | >1.1 | - | >1.1 |
| Anti-rubella IgG (IU/ml) | 0 (↓) | - | ≥15 | - | ≥15 |
| Lymphocyte subsets | |||||
| CD3+ T cell (%) | 42.3 (↓) | 46.6 (↓) | 51–85.3 | 61.3 | 51.7–84.1 |
| CD3+ T cell, count (/mm3) | 1987 (↓) | 2840 | 2340–7300 | 1890 | 1882–7372 |
| CD3+ CD4+ T (%) | 36.3 | 44.2 | 29.7–63.6 | 21.7 | 29.2–58 |
| CD3+ CD4+ T count (/mm3) | 1700 | 2696 | 1479–5050 | 672 | 1211–4696 |
| CD3+ CD8+ T (%) | 6.1 (↓) | 1.2 (↓) | 11.5–33.7 | 37.2 | 14–31 |
| CD3+ CD8+ T count (/mm3) | 287 (↓) | 73 (↓) | 584–2617 | 1147 | 567–2494 |
| CD19+ B cell (%) | 37.4 | 28.5 | 7.9–53.6 | 27.9 | 13–37 |
| CD19+ B cell, count (/mm3) | 1757 | 1738 | 450–3743 | 868 | 526–3126 |
| CD16+56+ NK cell (%) | 5 | - | 2.3–17.2 | 6.9 | 2–26 |
| CD16+56+ NK cell count (/mm3) | 235 | - | 163–894 | 214 | 105–1461 |
| Naive B cell (%) | 73 (↓) | - | 77–99 | 88.8 | 69–97 |
| NS B cell (%) | 10.7 | - | 3–13 | 4.1 | 3.6–19 |
| CS B cell (%) | 12 | - | 0.8–12 | 1.3 | 2–17 |
| CD21low CD38low activated B (%) | 2.9 | - | 0.7–6.9 | 7.4 | 0.9–9 |
| CD3+ TCRα/β cells (%) | 81.2 (↓) | - | 90–99.2 | 88.3 | 87–98 |
| CD3+ TCRγ/δ cells (%) | 9.1 | - | 2–10 | 4.8 | 2–14 |
| Recent thymic emigrants (%) | 12.8 (↓) | - | 63–90 | 54.9 | 60–83 |
| CD4+ CD45RA+ CCR7+ T cell (%) | 17.9 (↓) | - | 62–98 | 54.4 | 52–97 |
| CD4 + CD45RA- CCR7+ T cell (%) | 21.8 | - | 2.6–54 | 15.8 | 8–38 |
| CD4+ CD45RA- CCR7- T cell (%) | 52.5 (↑) | - | 0.1–13 | 25.3 | 0.3–11 |
| CD4+ CD45RA+ CCR7- T cell (%) | 7.7 | - | 0.1–76.3 | 4.5 | 0.2–55 |
| CD8+ CD45RA+ CCR7+ T cell (%) | 1.25 (↓) | - | 34–91.5 | 12.3 | 26.3–90 |
| CD8+ CD45RA- CCR7+ T cell (%) | 24.6 (↓) | - | 0.4–15.5 | 1.9 | 0.9–8.1 |
| CD8+ CD45RA- CCR7- T cell (%) | 68.3 (↓) | - | 1–68 | 42.8 | 3–40 |
| CD8+ CD45RA+ CCR7- T cell (%) | 5.8 (↑) | - | 9.6–70 | 42.9 | 13–69 |
| T-cell proliferation (anti-CD3/CD28; %) | - | Undetectable | 50–65 | 62 | 50–65 |
Note: Abnormal values are indicated in the parenthesis
Abbreviations: CS: Class switched, IVIG: Intravenous immunoglobulin, NS: Non-class switched, (-): Not done.